UBS Group’s Annovis Bio ANVS Stock Holding History

UBS Group’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,000	Closed	-$144K	–	9476
2024 Q2	$144K	Buy	+25,000	New	+$203K	﹤0.01%	5899

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's ANVS Position: Q2 2026 in Review

UBS Group reduced its Annovis Bio (ANVS) stake by 45% in Q2 2026, selling an estimated $19K and leaving 11,775 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8106.

UBS Group first reported a position in ANVS in Q2 2021 and has held it in 17 quarters since. The position peaked at $245K in Q4 2024. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

UBS Group held 11,775 shares of Annovis Bio worth $21.9K as of Q2 2026.
UBS Group sold 9,763 Annovis Bio shares in Q2 2026, an estimated $19K.
Annovis Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8106 holding.
UBS Group first reported a position in Annovis Bio in Q2 2021 and has held it in 17 quarters since.
UBS Group's Annovis Bio position peaked at $245K in Q4 2024.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.